NCT01528085已完成2 期
An Open Label Phase II Study to Evaluate the Efficacy and Safety of Induction and Consolidation Therapy With Nilotinib in Combination With Chemotherapy in Patients Aged 55 Years and Over With Philadelphia Chromosome Positive (Ph+ or BCR-ABL+) Acute Lymphoblastic Leukemia (ALL)
Goethe University138 个研究点 分布在 2 个国家目标入组 79 人开始时间: 2012年1月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 79
- 试验地点
- 138
- 主要终点
- Evaluation of efficacy of a nilotinib-based induction and consolidation therapy
研究概览
简要总结
The goal of this trial is to evaluate the efficacy and the tolerance of the combination of nilotinib with chemotherapy in the front-line setting as induction and consolidation therapy in Ph+ ALL patient aged 55 years and over. A European consensus has been reached to adopt a common chemotherapeutic schedule for patients aged 55 years and over. This schedule will be used in this trial with the addition of nilotinib as concomitant therapy during induction, consolidation and maintenance. The patients will be prospectively monitored for minimal residual disease and bcr-abl tyrosine kinase domain mutations.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 55 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients > 55 years
- •Philadelphia chromosome- or BCR-ABL positive acute lymphoblastic leukemia
- •Not previously treated except with corticosteroids or single dose vincristine (three doses cyclophosphamide accepted)
- •With or without documented CNS involvement
- •WHO performance status < 2
- •Normal serum levels > LLN (lower limit of normal) of potassium, magnesium, total calcium corrected for serum albumin; or corrected to within normal limits with supplements, prior to the first dose of study medication
- •Signed written inform consent
- •Molecular evaluation for BCR-ABL performed
- •Willingness of male subjects whose sexual partners are women of child-bearing potential (WOCBP), to use an effective form of contraception (pearl index < 1%), such as complete sexual abstinence, combined oral contraceptive, hormone IUCD, vaginal hormone ring, transdermal contraceptive patch, contraceptive implant or depot contraceptive injection in combination with a second method of contraception like a condom or a cervical cap / diaphragm with spermicide or surgical sterilisation (vasectomy) in male patients during the study and at least 6 months thereafter. WOCBP are defined as sexually mature women who have not undergone a hysterectomy or surgical sterilization or who have not been naturally postmenopausal for at least 12 consecutive months (i.e., who has had menses any time in the preceding 12 consecutive months).
排除标准
- •Patient previously treated with tyrosine kinase inhibitors
- •Known impaired cardiac function, including any of the following:
- •LVEF < 45%
- •Complete left bundle branch block
- •Right bundle branch block plus left anterior hemiblock, bifascicular block
- •Use of a ventricular-paced pacemaker
- •Congenital long QT syndrome
- •History of or presence of clinically significant ventricular or atrial tachyarrhythmias
- •Clinically significant resting bradycardia (< 50 beats per minute)
- •QTcF>450 msec on screening ECG. If QTc > 450 msec and electrolytes are not within normal ranges before nilotinib dosing, electrolytes should be corrected and then the patient rescreened for QTcF criterion.
- •Myocardial infarction with 12 months prior to starting nilotinib
- •Other clinical significant heart disease (e.g. unstable angina, congestive heart failure, uncontrolled hypertension)
- •Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention
- •Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not mandatory) or known infection with Hepatitis B or C
- •Treatment with any, other investigational agent or participating in another trial within 30 days prior to entering this study
- •Inadequate hepatic functions defined as ASAT or ALAT > 2,5 times the institutional upper limit of normal or > 5 times ULN if considered due to leukemia
- •Total bilirubin > 2 fold the institutional upper limit unless considered to be due to organ involvement by the leukemia or to M. Gilbert / M. Meulengracht
- •Concurrent severe diseases which exclude the administration of therapy
- •Past history of acute or chronic pancreatits
- •Patients unwilling or unable to comply with the protocol.e branch block; Right bundle branch block plus left anterior hemiblock, bifascicular block; Use of a ventricular-paced pacemaker; congenital long QT syndrome
- •History of or presence of clinically significant ventricular or atrial tachyarrhythmias
- •Clinically significant resting bradycardia (< 50 beats per minute)
- •QTcF>450 msec on screening ECG. If QTc > 450 msec and electrolytes are not within normal ranges before nilotinib dosing, electrolytes should be corrected and then the patient rescreened for QTcF criterion.
- •Myocardial infarction with 12 months prior to starting nilotinib
- •Other clinical significant heart disease (e.g. unstable angina, congestive heart failure, uncontrolled hypertension)
- •Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention
- •Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not mandatory) or known infection with Hepatitis B or C
- •Treatment with any, other investigational agent or participating in another trial within 30 days prior to entering this study
- •Inadequate hepatic functions defined as ASAT or ALAT > 2,5 times the institutional upper limit of normal or > 5 times ULN if considered due to leukemia
- •Total bilirubin > 2 fold the institutional upper limit unless considered to be due to organ involvement by the leukemia or to M. Gilbert / M. Meulengracht
- •Concurrent severe diseases which exclude the administration of therapy
- •Past history of acute or chronic pancreatits
- •Patients unwilling or unable to comply with the protocol.
结局指标
主要结局
Evaluation of efficacy of a nilotinib-based induction and consolidation therapy
时间窗: after 12 months
rate of patients without event
次要结局
- Event free survival
- Overall survival
- complete molecular response
- complete haematological remission(after induction treatment (week 5))
- Relapse free survival
- molecular relapse or progression
- Tolerability
- Death during induction(End of induction (week 5))
- Death in complete remission
- major molecular response in bone marrow
- undetectable BCR-ABL level
- Progression free survival
- T315I or p-loop Mutations
研究者
Heike Pfeifer MD
Dr.med.
Goethe University
研究点 (138)
Loading locations...
相似试验
终止
1 期
Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT01222143University Health Network, Toronto12
终止
1 期
An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)LeukemiaNCT02225574M.D. Anderson Cancer Center1
进行中（未招募）
2 期
The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBCTriple Negative Breast CancerNCT04877821Guangdong Provincial People's Hospital31
已完成
2 期
Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line TherapyNasopharyngeal CarcinomaNCT03906058Sun Yat-sen University39
终止
2 期
Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast CancerMetastatic Breast CancerNCT00597597Rush University Medical Center11